Rethinking Strategies to Select Antibiotic Therapy inClostridium difficileinfection
| Autor: | Sherwood L. Gorbach, Ellie J. C. Goldstein, Teena Chopra |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty 030106 microbiology Disease Global Health Severity of Illness Index 03 medical and health sciences Recurrence medicine Humans Pharmacology (medical) Fidaxomicin Prospective cohort study Intensive care medicine Clostridioides difficile business.industry Public health Clostridium difficile Anti-Bacterial Agents Surgery Clinical trial Metronidazole Practice Guidelines as Topic Clostridium Infections Vancomycin Public Health business Algorithms medicine.drug |
| Zdroj: | Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 36:1281-1289 |
| ISSN: | 0277-0008 |
| DOI: | 10.1002/phar.1863 |
| Popis: | In recent years, Clostridium difficile infection (CDI) has become a global public health threat associated with increased morbidity, mortality, and economic burden, all of which are exacerbated with disease recurrence. Current guidelines informing treatment decisions are largely based on definitions of disease severity at diagnosis, with subjective components not well delineated across treatment algorithms and clinical trials. Furthermore, there is little evidence linking severity at onset to outcome. However, reducing the risk of recurrence may offer both a better outcome for the individual and decreased downstream economic impact. The authors present data supporting the opinion that patients deemed at low risk for recurrence should receive vancomycin (or metronidazole when cost is an issue), while those at higher risk of recurrence would benefit from fidaxomicin treatment. Although further prospective studies are needed, choosing treatment with the goal of preventing recurrent CDI may offer a better guide than disease severity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text